SCHEMBL14491

SCHEMBL14491

O=C(c1ccccc1)n1c(=O)cc[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMP P19971 1/20 0.49
P2RX4 Q99571 2/20 0.47
IDO1 P14902 1/20 0.44
SRC P12931 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
ELANE P08246 1/20 0.40
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 2/20 0.39
PKM P14618 1/20 0.39
AGTR1 P30556 1/20 0.38
CHRNB2 P17787 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28545719 0.84 ALDH1A1 (0.50) TYMPP2RX4IDO1SRCSIGMAR1
SCHEMBL3015728 0.76 TYMP (0.54) TYMPP2RX4IDO1SRCSIGMAR1
SCHEMBL28132698 0.76 MAP2K1 (0.35) ALDH1A1MAPTPOLBKMT2ANAPRT
SCHEMBL11560902 0.74 TSHR (0.47) TYMPP2RX4IDO1SIGMAR1GSK3A
SCHEMBL2899212 0.74 TYMP (0.45) TYMPP2RX4IDO1SRCSIGMAR1
SCHEMBL11792243 0.73 P2RX4 (0.59) TYMPP2RX4IDO1SRCSIGMAR1
SCHEMBL31621004 0.73 TYMP (0.60) TYMPP2RX4IDO1SRCSIGMAR1
SCHEMBL28393438 0.73 CYP3A4 (0.51) IDO1ALDH1A1MAPTPOLBKMT2A
SCHEMBL5860460 0.73 LMNA (0.49) GSK3AGSK3BALDH1A1MAPTKMT2A
SCHEMBL3676684 0.72 SIGMAR1 (0.42) TYMPP2RX4IDO1SIGMAR1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678646-A1 NUCLEOSIDE ANALOG FOR 5'-PHOSPHONATE MODIFICATION AND OLIGONUCLEOTIDE PREPARED THEREFROM Shanghai Argo Biopharmaceutical Co., Ltd. (CN) 2026-01-14 EP claimed
WO-2024208249-A1 NUCLEOSIDE ANALOG FOR 5'-PHOSPHONATE MODIFICATION AND OLIGONUCLEOTIDE PREPARED THEREFROM 上海舶望制药有限公司 2024-10-10 WO claimed
US-20130310403-A1 Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer EWHA UNIVERSITY - INDUSTRY COLABORATION FOUNDATION (KR) 2013-11-21 US claimed
US-20020072586-A1 Chiral peptide nucleic acids ISIS INNOVATION LIMITED (GB) 2002-06-13 US claimed
US-6403763-B1 Chiral peptide nucleic acids ISIS INNOVATION LIMITED (GB) 2002-06-11 US claimed
EP-0956297-A1 CHIRAL PEPTIDE NUCLEIC ACIDS ISIS INNOVATION LIMITED (GB) 1999-11-17 EP claimed
WO-1998016550-A1 CHIRAL PEPTIDE NUCLEIC ACIDS ISIS INNOVATION LIMITED (GB) 1998-04-23 WO claimed
US-4914105-A NONTOXIC, REDUCED SIDE EFFECTS FUJII SETSURO (JP) 1990-04-03 US claimed
JP-58198500-A None JP disclosed
WO-2026098737-A1 NUCLEIC ACID CONJUGATE AND PHARMACEUTICAL COMPOSITION FOR LIPID DELIVERY, AND USE THEREOF 苏州时安生物技术有限公司 2026-05-15 WO disclosed
WO-2026098677-A1 DOUBLE-STRANDED RNA FOR REGULATING ALK7 EXPRESSION, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 苏州时安生物技术有限公司 2026-05-15 WO disclosed
WO-2026101522-A1 2'-FLUORO-6'METHYLENE CARBOCYCLIC NUCLEOSIDES AND NUCLEOTIDES AND METHODS OF TREATING POXVIRUS INFECTIONS WITH SAME UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2026-05-15 WO disclosed
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-23 US disclosed
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-02 US disclosed
JP-S58198500-A RIBONUCLEOSIDE SUBSTITUTED WITH 4-METHOXYBENZYL GROUP IN THE 2'-POSITION MITSUI TOATSU CHEM INC 1983-11-18 JP disclosed
EP-0045944-B1 ENHANCER OF ANTI-TUMOR EFFECT Yamasa Shoyu Kabushiki Kaisha (JP) 1983-08-31 EP disclosed
EP-0079054-A1 Enhancer of antitumor effect Yamasa Shoyu Kabushiki Kaisha (JP) 1983-05-18 EP disclosed
EP-0068268-A1 Enhancer of anti-tumour effect Yamasa Shoyu Kabushiki Kaisha (JP) 1983-01-05 EP disclosed
EP-0048022-A2 Enhancer of anti-tumor effect Yamasa Shoyu Kabushiki Kaisha (JP) 1982-03-24 EP disclosed
EP-0045944-A1 Enhancer of anti-tumor effect Yamasa Shoyu Kabushiki Kaisha (JP) 1982-02-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310403-A1 Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer NME1, NTPCR, ENTPD5 TYMP 45/4885P2RX4 1835/4885IDO1 4647/4885
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GPR119 TYMP 4811/4885P2RX4 402/4885IDO1 1978/4885
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GCGR TYMP 4798/4885P2RX4 433/4885IDO1 2592/4885
US-20020072586-A1 Chiral peptide nucleic acids POLL, HNRNPL, HLA-B TYMP 467/4885P2RX4 4504/4885IDO1 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.